Application of anti-CD20 monoclonal antibody in the treatment of active systemic lupus erythematosus / 基础医学与临床

ABSTRACT

To identify the clinical efficacy,immunological consequences and adverse effects of anti-CD20 monoclonal antibody in systemic lupus erythematosus.Nearly 100 patients have been reported and a 80% of them achieved marked reduction in global disease activity and clinical remission in lupus nephritis.Anti-CD20 monoclonal antibody is well tolerated in 90% of the patients,though10% of them had hypersensitivity reactions and 4 patients had severe opportunistic infection.